Drug Trial Radar · NCT05797168
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
622
Planned (sponsor's estimate)
Start
Jun 5, 2023
Primary completion
Aug 4, 2028
Study completion Aug 4, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
Conditions
- Ovarian Cancer
- Lung Adenocarcinoma
- Endometrial Cancer
- Lung Squamous Cell Carcinoma
Interventions
Torvutatug samrotecanDrug
IV Antibody-drug conjugate
SaruparibDrug
Oral PARP inhibitor
BevacizumabDrug
IV Monoclonal antibody
CarboplatinDrug
IV Alkylating agent
PalacaparibDrug
Oral PARP inhibitor
PembrolizumabDrug
IV Biologic
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events/serious adverse eventsTime frame: From time of Informed Consent to 30 days post last dose.
- The number of participants with dose limiting toxicity(DLT), as defined in the protocolTime frame: From the first dose of torvu-sam on Cycle 1 Day 1 up to and including the planned end of Cycle 1 (At the end of 21 days)
Locations
60 sites in 12 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California · Recruiting
Research Site
Irvine, California · Recruiting
Research Site
La Jolla, California · Withdrawn
Research Site
Aurora, Colorado · Recruiting
Research Site
Louisville, Kentucky · Terminated
Research Site
Boston, Massachusetts · Recruiting
Research Site
Detroit, Michigan · Recruiting
Research Site
Columbus, Ohio · Recruiting
Research Site
Portland, Oregon · Recruiting
Research Site
Providence, Rhode Island · Recruiting
Research Site
Providence, Rhode Island · Withdrawn
Research Site
Houston, Texas · Recruiting
Research Site
Fairfax, Virginia · Recruiting
Research Site
Liverpool, Australia · Recruiting
Research Site
Melbourne, Australia · Recruiting
Research Site
Edmonton, Alberta, Canada · Recruiting
Research Site
London, Ontario, Canada · Recruiting
Research Site
Toronto, Ontario, Canada · Recruiting
Research Site
Montreal, Quebec, Canada · Recruiting
Research Site
Montreal, Quebec, Canada · Recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Chongqing, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Jinan, China · Recruiting
Research Site
Xi'an, China · Recruiting
Research Site
Zhengzhou, China · Terminated
Research Site
Berlin, Germany · Recruiting
Research Site
Essen, Germany · Recruiting
Research Site
Freiburg im Breisgau, Germany · Recruiting
Research Site
Hanover, Germany · Recruiting
Research Site
Leipzig, Germany · Recruiting
Research Site
Mannheim, Germany · Recruiting
Research Site
Regensburg, Germany · Recruiting
Research Site
Haifa, Israel · Recruiting
Research Site
Ramat Gan, Israel · Recruiting
Research Site
Hidaka-shi, Japan · Recruiting
Research Site
Kashiwa, Japan · Recruiting
Research Site
Kōtoku, Japan · Recruiting
Research Site
Sunto-gun, Japan · Recruiting
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.